Back

Looking to connect with folks in clinical diagnostics and molecular biology! I’m building a new clinical lab focused on infectious disease diagnostics powered by DNA sequencing — and would love to connect with people who have experience in: • Runni

Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren

A genetic testing company is pitching on Shark Tank tomorrow—possibly the first biotech startup to enter the tank! 🦈 <> 🧬 Curious to see how the sharks react to DNA sequencing and whether they’ll bite. Is the product legit? Will they challenge th

From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power

Why qPCR & Phenotypic Testing Must Be Displaced – Part II If you ever want to understand the scale of a problem, look at how much it costs. Tuberculosis alone costs India, Africa, and Brazil 27 trillion INR a year in lost productivity and healthcare

‼️ A story of genetic Biotechnology based startup from India Too much of AI and Buzzy things, how about the budding industry with high potential - Genetic Technology Mapmygenome, an initiative started in 2013 by Anu Acharya, a resident of Hyderaba

🚨 The magic number: ₹800 Cr ⸻ VCs invest in businesses that can be big enough to return their entire fund. To get VCs interested, your startup must at least have the potential to reach ₹800 Cr+ in annual revenue or ₹8,000 Cr+ in market cap (assumi